Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

An Ancient Anti-cancer Mechanism: DISE

News

October 3, 2023
PRESS RELEASE: On September 25, 2023, a new editorial was published in Oncotarget, entitled, “DISE, an ancient anti-cancer mechanism that senses mutational load in cancerous cells?” continue reading »

Reassessing COVID-19 Precautions in 2023

News

September 27, 2023
PRESS RELEASE: On September 22, 2023, a new editorial was published in Oncotarget, entitled, “Reassessing the risks and benefits of COVID-19 precautions in 2023.” continue reading »

Four Novel Receptors May Link Endometrial Cancer to PCOS

News

September 25, 2023
On September 22, 2023, a new research paper was published in Oncotarget, entitled, “Transcriptomic analysis identifies four novel receptors potentially linking endometrial cancer with polycystic ovary syndrome and generates a transcriptomic atlas.” continue reading »

Targeting Fatty Acid Binding Proteins in Multiple Myeloma

Oncotarget

September 21, 2023
In a recent editorial, researchers discuss targeting fatty acid binding proteins to fight multiple myeloma. continue reading »

DPP4 Inhibitors for Target Therapy Resistance in Renal Cell Carcinoma

News

September 20, 2023
PRESS RELEASE: On September 15, 2023, a new editorial was published in Oncotarget, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma.” continue reading »